SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3588-3594. Prepublished online as a Blood First Edition Paper on December 7, 2006; DOI 10.1182/blood-2006-07-036848. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-07-036848v1 109/8/3588    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Crawley, C. Articles by Gahrton, G. Search for Related Content PubMed PubMed Citation Articles by Crawley, C. Articles by Gahrton, G. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 28, 2006 Accepted November 27, 2006 Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning Charles Crawley*, Simona Iacobelli, Bo Bjorkstrand, Jane F. Apperley, Dietger Niederwieser, and Gosta Gahrton Addenbrooke's Hospital, Cambridge, United Kingdom Department of Medical Statistics, Leiden University Medical Center, Leiden, Netherlands Karolinska University Hospital, Stockholm, Sweden Imperial College, Hammersmith Hospital, London, United Kingdom University of Leipzig, Leipzig, Germany * Corresponding author; email: charles.crawley{at}addenbrookes.nhs.uk. Despite the widespread adoption of reduced intensity conditioning (RIC) for myeloma there are few data comparing outcomes with RIC with myeloablative conditioning (MAC). We report the outcomes of patients undergoing allogeneic transplants for myeloma and reported to the EBMT. A minimum data set was available on 320 RIC and 196 MAC allografts performed between 1998-2002. The RIC patients were older (51 vs 45yrs) with more progressive disease (28% vs 21%) and more had received a prior transplant (76% vs 11%), In addition there was a longer time to transplant and an increased use of peripheral blood and T cell depletion. The non relapse mortality (NRM) at 2 yrs was 24% and 37% (p=0.002) for RIC and MAC respectively with the overall survival being 38.1% and 50.8% (ns) and progression free survival (PFS) 18.9% vs 34.5% (p=0.001). On multivariate analysis RIC was associated with a reduction in NRM (HR 0.5) but this was offset by an increase in relapse risk (HR 2.0) and the conditioning intensity did not impact on overall survival or retain significance for PFS. These data suggest that there is a continuing need to investigate dose intensity in the conditioning for myeloma allografts. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Nonmyeloablative allotransplantation for myeloma: light and shade Michele Cavo Blood 2007 109: 3134-3135. [Full Text] [PDF] This article has been cited by other articles: N. Schmitz, A. Sureda, G. Dini, A. Claviez, and on behalf of the Lymphoma and Pediatric Diseases W Allogeneic transplantation for children and adolescents with Hodgkin lymphoma Blood, November 12, 2009; 114(20): 4605 - 4606. [Full Text] [PDF] S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood, October 8, 2009; 114(15): 3276 - 3284. [Abstract] [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] S. O. Schonland, N. Kroger, C. Wolschke, P. Dreger, A. D. Ho, and U. Hegenbart Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect" Haematologica, March 1, 2009; 94(3): 439 - 441. [Full Text] [PDF] P. Moreau, F. Garban, M. Attal, M. Michallet, G. Marit, C. Hulin, L. Benboubker, C. Doyen, M. Mohty, I. Yakoub-Agha, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma Blood, November 1, 2008; 112(9): 3914 - 3915. [Full Text] [PDF] G. Gahrton and B. Bjorkstrand Allogeneic transplantation in multiple myeloma Haematologica, September 1, 2008; 93(9): 1295 - 1300. [Full Text] [PDF] F. Ayuk, J. A. Perez-Simon, A. Shimoni, A. Sureda, T. Zabelina, R. Schwerdtfeger, R. Martino, H. G. Sayer, A. Alegre, J.-J. Lahuerta, et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation Haematologica, September 1, 2008; 93(9): 1343 - 1350. [Abstract] [Full Text] [PDF] G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma Haematologica, November 1, 2007; 92(11): 1513 - 1518. [Abstract] [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020